Development of halo nevi in a lung cancer patient: A novel immune-related cutaneous event from atezolizumab

Mathew R. Birnbaum, Michelle W. Ma, Michael A. Casey, Bijal D. Amin, Mark Jacobson, Haiying Cheng, Beth N. McLellan

Research output: Contribution to journalArticle

3 Scopus citations


Immunotherapy-induced vitiligo is an immune-related adverse event (irAE) observed in metastatic melanoma patients treated with immune checkpoint inhibitors that target the cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) pathways. To date, the development of leukoderma, poliosis, and halo nevi during immunotherapy has largely been reported in metastatic melanoma patients. We report a case of immunotherapy-induced leukoderma presenting as halo nevi in a patient with non-small cell lung cancer (NSCLC) treated with atezolizumab, a programmed cell death ligand (PD-L1) antibody. Immunotherapy-induced vitiligo in metastatic melanoma patients may be associated with improved survival, but it remains to be determined whether its occurrence in nonmelanoma cancers has the same prognostic significance.

Original languageEnglish (US)
Pages (from-to)1047-1049
Number of pages3
JournalJournal of Drugs in Dermatology
Issue number10
Publication statusPublished - Oct 1 2017


ASJC Scopus subject areas

  • Dermatology

Cite this